Charles River is consistently collecting new information and testing new technology to enhance all of our oncology models. Recently, at the 28th EORTC-NCI-AACR Symposium, we presented data on our evaluation of multiple humanized mouse platforms being used daily to test a wide variety of therapies in our facilities. These models include PBMC and CD34+ engrafted mice with human xenograft cell line or patient-derived xenograft tumors that can be used for standard format studies as well as the Single Mouse Trial screening format.
We also had the opportunity to present a comprehensive picture of our well-characterized PDX model collection, which is available via our easy-to-access online tumor compendium tool. This collection includes over 400 models covering all major cancer types that have been extensively profiled for histological features, molecular data, and tumor growth with sensitivity to standard of care compounds and targeted therapies.
Click the links below to view the data.
Combination Immune Checkpoint Inhibitors for the Treatment of Human Colon Carcinoma in NSG Mice Engrafted with Human PBMC
Development and Validation of a PDX-based Preclinical Platform for Immuno-oncology Drug Development
The Charles River PDX Compendium: A Database of Well-characterized PDX Models with Molecular and Drug Sensitivity Profiles for Preclinical Studies